Last reviewed · How we verify

GSK2269557 — Competitive Intelligence Brief

GSK2269557 (GSK2269557) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: HDAC6 inhibitor. Area: Oncology.

phase 2 HDAC6 inhibitor HDAC6 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

GSK2269557 (GSK2269557) — GlaxoSmithKline. GSK2269557 is a selective inhibitor of the histone deacetylase 6 (HDAC6).

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
GSK2269557 TARGET GSK2269557 GlaxoSmithKline phase 2 HDAC6 inhibitor HDAC6
Vorinostat (VOR) Vorinostat (VOR) University of North Carolina, Chapel Hill marketed Histone deacetylase (HDAC) inhibitor Histone deacetylases (HDAC1, HDAC2, HDAC3, HDAC6, HDAC8)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (HDAC6 inhibitor class)

  1. CrystalGenomics, Inc. · 1 drug in this class
  2. GlaxoSmithKline · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). GSK2269557 — Competitive Intelligence Brief. https://druglandscape.com/ci/gsk2269557. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing